Vivos Inc. Business Updates
Vivos Inc. is pleased to offer business updates for the most accurate and up to date information.
Featured:
September 2026 Highlights
September 2026 · Summary of Activities Implementing the Strategic Plan Earlier this month, we conducted our Business Strategy Advisory Board meeting, where we reached consensus on the actions required to…
RadioGel® IRB Update: Vivos Builds on FDA IDE Approval as Mayo Clinic Process Advances
Kennewick, Wash. — September 15, 2026 – Vivos Inc. (OTCQB: RDGL) (“Vivos” or the “Company”) is pleased to provide shareholders with an update on the continued advancement of its U.S.…
Vivos Inc. Launches New Corporate Website in Partnership with Award-Winning PixelRank
Kennewick, WA – July 14, 2026 – Vivos Inc. (OTCQB: RDGL) is pleased to announce that it has been working closely with PixelRank, led by Founder and CEO Dave Brinkhus…
Vivos Inc. Announces Acceptance of Abstract for Presentation at the American College of Veterinary Surgeons (ACVS) Surgical Summit
Kennewick, WA – July 8, 2026 – Vivos Inc. (OTCQB: RDGL) is pleased to announce that its abstract titled “Postoperative Precision Radionuclide Brachytherapy for Incomplete Tumor Resection” has been accepted…
Vivos Inc. (OTCQB: RDGL) Announces Receipt of Washington State Radioactive Materials License for IsoPet ® Manufacturing
Kennewick, WA – June 11, 2026 – Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is pleased to announce…
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
Kennewick, WA – June 5, 2026 – Vivos Inc. (OTCQB: RDGL), a company pioneering Precision Radionuclide Therapy™ (PRnT) with its innovative RadioGel® technology, today announced the submission of its Early…
Vivos Inc. Reports Positive Independent Drug Elution Data Validating PrecisionGel™ for Sustained Localized Delivery
Kennewick, Wash. — Vivos Inc. (“Vivos” or the “Company”) announced today the successful completion of independent third-party drug elution testing evaluating the controlled-release performance of the Company’s proprietary PLGA-g-PEG thermogelling…
Vivos Inc. Completes Enrollment in Study of Postoperative Precision Radionuclide Therapy for Incomplete Tumor Resection
KENNEWICK, WA – May 11, 2026 – Vivos Inc. (OTCQB: RDGL) is pleased to provide the following update regarding its latest study on IsoPet® Postoperative Precision Radionuclide Therapy™ (PRnT). Initial…
Business Update on the FDA Investigational Device Exemption (IDE) Regulatory Submission for RadioGel® Precision Radionuclide Therapy™
Vivos Inc. is providing an update to shareholders regarding its FDA regulatory pathway for RadioGel®. The Company continues to make substantial progress towards the submission of its Investigational Device Exemption…